How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients.
Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic profiling for the prognosis and predicting benefit...
| Publicado en: | Current Oncology Vol. 28; no. 1; pp. 800 - 813 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Feb2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |